What’s Ahead For CAR-T Play Kite Pharma? – Seeking Alpha
FierceBiotech |
What's Ahead For CAR–T Play Kite Pharma?
Seeking Alpha Also a CAR–T therapy, KITE-585 is being evaluated for the treatment of multiple myeloma (plasma cell cancer) through the targeting of B-cell maturation antigen (BCMA), which has been implicated in other lymphomas and leukemia. The company expects to … The FDA priority review gives Kite's CAR–T a PDUFA date of November 29 |
